Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?

Japan approval puts BRINSUPRI in all three major Insmed markets

Insmed (INSM) has received approval from Japan's Ministry of Health, Labour and Welfare for BRINSUPRI tablets in non-cystic fibrosis bronchiectasis. The drug is now cleared in the U.S., Europe, and Japan.

This move adds another commercial jurisdiction for BRINSUPRI and follows Phase 3 ASPEN data in non cystic fibrosis bronchiectasis. For investors, it further connects the Insmed story to this therapy and its global uptake.

Insmed shares trade at US$121.84 after a 1 day share price return of 2.78%, with recent news around BRINSUPRI coinciding with a 30 day share price return of 23.57% that contrasts with a year to date share price decline of 31.21%.

Over a longer horizon, total shareholder return has declined 10.48% over the past year. However, the 3 year and 5 year total shareholder returns of very large multiples indicate that longer term holders have still seen substantial gains as the market has reassessed both growth prospects and risks around Insmed’s pipeline and approvals such as BRINSUPRI.

Scan other rare disease and specialist therapy opportunities that are moving on fresh approvals or trial results with our hand picked 19 high quality undiscovered gems.

After the Japan approval and a sharp 30 day move, Insmed trades at US$121.84. The average analyst target and internal fair value work still indicate a materially higher level. Where does a reasonable fair value anchor now sit within that range?

Most Popular Narrative: 38.2% Undervalued

Insmed's most widely followed narrative pegs fair value at about $197 per share, compared to the last close at $121.84. This frames the current discount and puts recent Japan approval news into a broader long term context.

The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid-2025 and brensocatib in CRS without nasal polyps by the end of 2025 are key clinical milestones that could enhance future revenue streams if positive.

Read the complete narrative.

Want to see what is driving that valuation gap for Insmed? The narrative leans heavily on aggressive revenue expansion, stronger margins and a rich future earnings multiple. Curious how those moving parts combine to support a fair value near $200?

Result: Fair Value of $197.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors also need to weigh the risk that any delay in U.S. brensocatib approvals or tougher payer reimbursement decisions could quickly challenge the Insmed valuation narrative.

Find out about the key risks to this Insmed narrative.

Another View on Insmed’s Valuation

The earlier narrative leans on a fair value of about $197 per Insmed share, which implies the stock is 38.2% undervalued. A simple revenue multiple paints a less generous picture. At a P/S of 23.4x, Insmed trades above the US Biotechs industry at 13.2x and above a fair ratio of 19.1x. That gap points to valuation risk if sentiment around growth or execution cools.

For investors weighing these opposing signals, the question is whether the stronger growth forecasts and pipeline justify paying a richer sales multiple today, or whether it makes more sense to wait for either fundamentals or price to move closer to that fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Feeling that the Insmed story is pulling in two directions with both risks and rewards on the table? Act quickly, review the underlying data for yourself, and then weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Insmed?

If Insmed has your attention, do not stop here. Broaden your watchlist with other focused ideas that could suit different risk levels and portfolio goals.

• Spot fresh potential and hunt for early stage opportunities using the 22 elite penny stocks with strong financials before they move out of reach.
• Prioritise value and put capital to work in companies that combine quality fundamentals with appealing prices through the 45 high quality undervalued stocks.
• Strengthen your defensive side and aim for smoother portfolio swings by scanning the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com